Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−51.98 M USD
0.00 USD
32.54 M
About Bicara Therapeutics Inc.
Sector
CEO
Claire Mazumdar
Headquarters
Boston
Website
Founded
2018
FIGI
BBG00Z15DGK7
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and it developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, is a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BCAX is 19.12 USD — it has increased by 1.97% in the past 24 hours. Watch Bicara Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Bicara Therapeutics Inc. stocks are traded under the ticker BCAX.
BCAX stock has risen by 11.16% compared to the previous week, the month change is a 9.19% rise, over the last year Bicara Therapeutics Inc. has showed a −27.16% decrease.
We've gathered analysts' opinions on Bicara Therapeutics Inc. future price: according to them, BCAX price has a max estimate of 48.00 USD and a min estimate of 36.00 USD. Watch BCAX chart and read a more detailed Bicara Therapeutics Inc. stock forecast: see what analysts think of Bicara Therapeutics Inc. and suggest that you do with its stocks.
BCAX reached its all-time high on Nov 6, 2024 with the price of 28.09 USD, and its all-time low was 16.01 USD and was reached on Dec 20, 2024. View more price dynamics on BCAX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BCAX stock is 6.22% volatile and has beta coefficient of 0.80. Track Bicara Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Bicara Therapeutics Inc. there?
Today Bicara Therapeutics Inc. has the market capitalization of 1.02 B, it has decreased by −8.89% over the last week.
Yes, you can track Bicara Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Bicara Therapeutics Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
BCAX earnings for the last quarter are −1.60 USD per share, whereas the estimation was −0.41 USD resulting in a −290.24% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Bicara Therapeutics Inc. earnings.
Bicara Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BCAX net income for the last quarter is −17.48 M USD, while the quarter before that showed −22.84 M USD of net income which accounts for 23.48% change. Track more Bicara Therapeutics Inc. financial stats to get the full picture.
No, BCAX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BCAX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bicara Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.